Drug Profile
Research programme: monoclonal antibodies diagnostics - Fujirebio
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fujirebio
- Class Monoclonal antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in Japan
- 03 Dec 2010 Preclinical trials in Cancer (diagnosis) in Japan (unspecified route)
- 19 Nov 2010 Pharmacodynamics data from a preclinical trial in Cancer presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)